Racura Oncology Ltd (RAC.AX)
ASX · AUD · Healthcare · Biotechnology
A$1.54 (-6.69%) as of
Key statistics
- Market cap
- 300.97M
- Forward P/E
- -14.90
- EPS (TTM)
- -0.0600
- Dividend yield
- 0.00%
- 52-week range
- 1.5200 – 3.7900
- Beta
- 0.91
- Revenue (TTM)
- 2.81M
- Profit margin
- 0.00%
- Volume
- 70.90k
About Racura Oncology Ltd
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Sydney, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.